Program
vamikibart
Also written as “Vamikibart”, “RO7200220” and “EBI-031”.
Its studies are mostly in Macular Edema, led by 2 companies.
Drug pageVamikibart: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 50 open or running | phase 3since Dec 6, 2022 | Dec 8, 2021 | none ahead |
| Eleven Biotherapeutics | 10 open or running | phase 1since Jul 19, 2016 | Jul 19, 2016 | none ahead |
- Named in Hoffmann-La Roche’s own pipeline as
RG6179 vamikibart
, phase 4, as of Oct 22, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eleven Biotherapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 19, 2016First study: phase 1 study in Diabetic Macular EdemaFirst studyNCT02842541
- Jan 19, 2023Named vamikibartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, RO7200220, EBI-031
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Eleven Biotherapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02842541Diabetic Macular Edema | 1 | Withdrawn | Oct 2017 | 0 |
How it is read
Names in the registry
- “Vamikibart”, 4 entries
- “RO7200220”, 1 entry
- “EBI-031”, 1 entry
Conditions, from the studies’ own filings
- Macular Edema, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.